A Case of Posterior Reversible Encephalopathy Syndrome With Single-Agent Weekly Paclitaxel
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological condition characterised by acute neurological symptoms and typical magnetic resonance imaging findings. It is commonly associated with hypertension, renal dysfunction, autoimmune conditions, and exposure to certain systemic anti-cancer therapy (SACT) agents. Although PRES has been reported with several chemotherapeutic drugs, its occurrence shortly after the first dose of single-agent weekly paclitaxel is exceptionally rare and not well-documented. We report the case of a 61-year-old female with metastatic breast cancer who developed acute confusion, focal seizures, and a reduced Glasgow Coma Scale (GCS) shortly after receiving her first dose of weekly paclitaxel (80 mg/m²) for visceral crisis. Prior to chemotherapy, she had no history of hypertension, neurological disease, or chronic kidney disease. Following paclitaxel administration, she developed transient hypertension and rapid neurological deterioration. The CT scan was normal. MRI confirmed findings consistent with PRES, showing bilateral parieto-occipital cortical-subcortical signal changes. Paclitaxel was withheld, and she was medically managed (antihypertensive, antiepileptic treatment, and corticosteroids), leading to gradual recovery. This case highlights PRES as a rare but serious potential complication of single-agent paclitaxel therapy. Clinicians should maintain a high index of suspicion for PRES in patients presenting with…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.